Key result
Bevacizumab administration in a patient with non-small-cell lung cancer was associated with a left ventricular wall perforation after myocardial infarction, which regressed on cardiac MRI follow-up.
Case Report (n=1)
This case highlights a rare but severe cardiac complication (left ventricular perforation post-MI) associated with the angiogenesis inhibitor Bevacizumab in a lung cancer patient.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to rare LV perforation risk with bevacizumab post-MI; leaves open causality and need for larger studies.
In addition to traditional chemotherapeutic regimens molecular targeted agents emerged as new therapeutic options for the treatment of non-small-cell lung cancer (NSCLC). These targeted therapies do not have the same systemic adverse effects usually observed with traditional cytotoxic drugs, but feature a specific spectrum of characteristic adverse effects. The humanized monoclonal antibody against the VEGF-A ligand Bevacizumab inhibits angiogenesis. The characteristic toxicities of Bevacizumab include hemorrhage, wound healing complications, gastrointestinal perforation, arterial thromboembolism, and infusion-related hypersensitivity reactions. We present a unique case of a left ventricular wall perforation after myocardial infarction associated with the administration of Bevacizumab in NSCLC. Cardiac MRI follow-up showed regression of the ventricular perforation.
No takes yet. Share an insight, caveat, or question.
Keßler et al. (2017) conducted a case report in Non-small-cell lung cancer (NSCLC) (n=1). Bevacizumab was evaluated on Left ventricular wall perforation after myocardial infarction. Bevacizumab administration in a patient with non-small-cell lung cancer was associated with a left ventricular wall perforation after myocardial infarction, which regressed on cardiac MRI follow-up.
Synapse has enriched 10 related papers. Consider them for comparative context: